CD274 and non-small cell lung carcinoma: A pooled analysis of phase 3 clinical trials previously reported that most patient subgroups with NSCLC and PD-L1 TPS ≥ 50% may achieve comparable or superior OS and PFS outcomes compared to MONO, whereas the outcomes of the subgroup analysis based on age in this study indicate that elderly patients receiving COMBO may not have improved outcomes over MONO (23).